Gender-related survival differences associated with polymorphic variants of estrogen receptor-Β (ERΒ) in patients with metastatic colon cancer

Pharmacogenomics Journal

Volumn 11, Issue 5, 2011, Pages 375-382

  Press, O A ^a   Zhang, W ^a   Gordon, M A ^a   Yang, D ^b   Haiman, C A ^b   Azuma, M ^a   Iqbal, S ^a   Lenz, H J ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

clinical outcome; colon cancer; ERb; ERb CA repeat polymorphism; gender; polymorphisms

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA 1; ESTROGEN RECEPTOR BETA 2; ESTROGEN RECEPTOR BETA 3; ESTROGEN RECEPTOR BETA 4; ESTROGEN RECEPTOR BETA 5; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASIAN; BONE METASTASIS; CANCER SURVIVAL; CAUCASIAN; COLON CANCER; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ETHNICITY; FEMALE; GALLBLADDER METASTASIS; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISPANIC; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; OVERALL SURVIVAL; PANCREAS METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; SPLEEN METASTASIS; TRANSCRIPTION INITIATION; TUMOR LOCALIZATION; VISCERAL METASTASIS;

3' UNTRANSLATED REGIONS; ADULT; AGED; CARCINOMA; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, GENETIC; PROGNOSIS; SEX FACTORS; TREATMENT OUTCOME;

EID: 80053563773     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.45     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424. (Pubitemid 30247142)
3. DeCosse JJ, Ngoi SS, Jacobson JS, Cennerazzo WJ. Gender and colorectal cancer. Eur J Cancer Prev 1993; 2: 105-115.
4. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 1998; 82: 1197-1207. (Pubitemid 28136536)
5. Gershbein LL. Action of estrogen and adrenocorticoids on adenocarcinoma induction by 1,2-dimethylhydrazine in male rats. Res Commun Chem Pathol Pharmacol 1993; 81: 117-120. (Pubitemid 23220537)
6. Ochiai M, Watanabe M, Kushida H, Wakabayashi K, Sugimura T, Nagao M. DNA adduct formation, cell proliferation and aberrant crypt focus formation induced by PhIP in male and female rat colon with relevance to carcinogenesis. Carcinogenesis 1996; 17: 95-98. (Pubitemid 26091276)
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333. (Pubitemid 34761611)
8. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999; 106: 574-582. (Pubitemid 29231110)
9. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999; 261: 521-527. (Pubitemid 29392509)
10. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60: 245-248. (Pubitemid 30070743)
11. Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep 2005; 14: 17-21.
12. Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC. Oestrogen-induced apoptosis in colonocytes expressing oestrogen receptor beta. J Endocrinol 2002; 174: 369-377.
13. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 2000; 161: 63-71.
14. Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res 2007; 67: 2366-2372. (Pubitemid 46437055)
15. Caiazza F, Galluzzo P, Lorenzetti S, Marino M. 17Beta-estradiol induces ERbeta up-regulation via p38/MAPK activation in colon cancer cells. Biochem Biophys Res Commun 2007; 359: 102-107. (Pubitemid 46839219)
16. Kennelly R, Kavanagh DO, Hogan AM, Winter DC. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol 2008; 9: 385-391. (Pubitemid 351411655)
17. Barone M, Tanzi S, Lofano K, Scavo MP, Guido R, Demarinis L et al. Estrogens, phytoestrogens and colorectal neoproliferative lesions. Genes Nutr 2008; 3: 7-13.
18. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11: 537-551. (Pubitemid 39331282)
19. Ugai K, Nishimura K, Fukino K, Nakamura T, Ueno K. Functional analysis of transcriptional activity of cytosine and adenine (CA) repeats polymorphism in the estrogen receptor beta gene. J Toxicol Sci 2008; 33: 237-240. (Pubitemid 351872365)
20. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Wolff RK, Potter JD et al. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2936-2942. (Pubitemid 43068828)
21. Lau HH, Ho AY, Luk KD, Kung AW. Estrogen receptor beta gene polymorphisms are associated with higher bone mineral density in premenopausal, but not postmenopausal southern Chinese women. Bone 2002; 31: 276-281. (Pubitemid 34814961)
22. Westberg L, Baghaei F, Rosmond R, Hellstrand M, Landen M, Jansson M et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001; 86: 2562-2568. (Pubitemid 32545707)
23. Westberg L, Ho HP, Baghaei F, Nilsson S, Melke J, Rosmond R et al. Polymorphisms in oestrogen and progesterone receptor genes: possible influence on prolactin levels in women. Clin Endocrinol (Oxf) 2004; 61: 216-223. (Pubitemid 39093117)
24. Vallbohmer D, Iqbal S, Yang DY, Rhodes KE, Zhang W, Gordon M et al. Molecular determinants of irinotecan efficacy. Int J Cancer 2006; 119: 2435-2442. (Pubitemid 44546969)
25. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. Estrogen receptor beta (ESR2 ) polymorphisms and endometrial cancer (United States). Cancer Causes Control 2004; 15: 627-633. (Pubitemid 39070081)
26. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176-13180.
27. Berry G, Kitchin RM, Mock PA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med 1991; 10: 749-755.
28. Rothman KJ. Modern Epidemiology. Lippincott-Raven: Philadelphia, 1998.
29. Forsell C, Enmark E, Axelman K, Blomberg M, Wahlund LO, Gustafsson JA et al. Investigations of a CA repeat in the oestrogen receptor beta gene in patients with Alzheimer's disease. Eur J Hum Genet 2001; 9: 802-804. (Pubitemid 33019169)
30. Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN. Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int 2004; 74: 501-508. (Pubitemid 38780285)
31. Shearman AM, Karasik D, Gruenthal KM, Demissie S, Cupples LA, Housman DE et al. Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 2004; 19: 773-781. (Pubitemid 41094389)
32. Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M et al. Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 2000; 269: 537-541. (Pubitemid 30440336)
33. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S. Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet 2000; 45: 327-330.
34. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J et al. Nuclear estrogen receptor beta in lung cancer: expression and survival differences by sex. Clin Cancer Res 2005; 11: 7280-7287. (Pubitemid 41507685)
35. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S et al. Genderrelated survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 2008; 68: 3037-3042. (Pubitemid 351556305)
36. Hitosugi T, Sasaki K, Sato M, Suzuki Y, Umezawa Y. Epidermal growth factor directs sex-specific steroid signaling through Src activation. J Biol Chem 2007; 282: 10697-10706. (Pubitemid 47093460)
37. Levin ER. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 2003; 17: 309-317. (Pubitemid 36315626)
38. Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G et al. EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int J Cancer 2004; 112: 78-86. (Pubitemid 39249494)
39. Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G et al. The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells. Steroids 2004; 69: 549-552. (Pubitemid 39013486)
40. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 2006; 24: 3562-3569. (Pubitemid 46630527)
41. Janakiram NB, Steele VE, Rao CV. Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethaneinduced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila Pa) 2009; 2: 52-59.
42. Traynor AM, Schiller JH, Stabile LP, Kolesar JM, Eickhoff JC, Dacic S et al. Pilot study of gefitinib and fulvestrant in the treatment of postmenopausal women with advanced non-small cell lung cancer. Lung Cancer 2009; 64: 51-59.